Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabeprazole + domperidone (Citrix Ltd)
- Development stage
- Unknown
- Lead developer
- Citrix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rebedolife-DSR is a fixed-dose combination medication marketed by Citrix Life Science, primarily used in the management of acid-peptic disorders. It consists of rabeprazole sodium, a substituted benzimidazole proton pump inhibitor (PPI), and domperidone, a peripheral dopamine D2 receptor antagonist. Rabeprazole suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. Domperidone acts as a prokinetic agent by increasing lower esophageal sphincter pressure and enhancing gastric emptying, which helps alleviate symptoms of nausea and bloating often associated with acid reflux. The "DSR" suffix typically denotes a sustained-release formulation of the domperidone component to provide prolonged symptomatic relief.
- Brand names
- Rebedolife-DSR
- Other names
- Rabeprazole sodium and domperidone sustained-release capsules
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on rabeprazole + domperidone (Citrix Ltd).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabeprazole + domperidone (Citrix Ltd).